Panel requires stricter safety criteria for blood system trial

11/17/2009 | Forbes

The FDA's Blood Products Advisory Committee has required Cerus to tighten safety parameters for a late-stage study involving its intercept blood system, which inhibits blood-borne pathogens in blood components used for transfusions. The company said it may take a year to finish preparations for the planned trial.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX